VENUSREM - Venus Remedies
📢 Recent Corporate Announcements
Venus Remedies Limited has announced the opening of a special window for shareholders to re-lodge transfer requests for physical shares. This move is in compliance with SEBI circulars dated July 02, 2025, and January 30, 2026. The company has actively disseminated this information across its official social media handles to ensure investor awareness. This is a procedural update aimed at assisting legacy shareholders with physical share certificates.
- Opening of a Special Window for re-lodgement of physical share transfer requests.
- Compliance with SEBI guidelines issued on July 02, 2025, and January 30, 2026.
- Information shared across Instagram, Facebook, LinkedIn, and X (formerly Twitter).
- Official notification submitted to NSE and BSE on March 10, 2026.
Venus Remedies has been notified of an internal merger between two of its promoter group entities, Sunev Pharma Solutions and Spine Software Systems. Under the approved Scheme of Amalgamation, Sunev will merge into Spine, resulting in the transfer of Sunev's 17.21% equity stake in Venus Remedies to Spine. This is a purely internal restructuring within the promoter group and does not involve Venus Remedies as a direct party. Importantly, there will be no change in the overall promoter group shareholding or the management control of the company.
- Sunev Pharma Solutions Private Limited to merge with and into Spine Software Systems Private Limited.
- A 17.21% equity stake in Venus Remedies will vest in Spine Software Systems upon the scheme becoming effective.
- The aggregate promoter and promoter group shareholding in Venus Remedies remains unchanged.
- The restructuring is subject to statutory and regulatory approvals and will not result in a change of control.
Venus Remedies reported a strong standalone performance for the quarter ended December 31, 2025, with net profit rising to ₹24.92 crore from ₹18.02 crore in the previous year. Revenue from operations grew to ₹179.95 crore, supported by improved operational efficiency as EBITDA rose to ₹39.13 crore. However, auditors raised an emphasis of matter regarding the German subsidiary, Venus Pharma GmbH, which has a negative net worth of ₹94.15 lakhs. Management expects a turnaround in the subsidiary's financial position by the end of FY 2025-26 through ongoing restructuring.
- Standalone Net Profit increased by 38.3% YoY to ₹24.92 crore in Q3 FY26.
- Revenue from operations for the quarter stood at ₹179.95 crore compared to ₹172.20 crore in Q3 FY25.
- EBITDA for the quarter improved significantly to ₹39.13 crore from ₹24.65 crore in the year-ago period.
- Auditors flagged a negative net worth of ₹94.15 lakhs at the German subsidiary, Venus Pharma GmbH.
- Share application money of ₹2,859.72 lakhs remains pending for allotment in the German subsidiary as part of strategic restructuring.
Venus Remedies has responded to exchange clarifications regarding clerical errors in its Q2 FY26 financial filings, specifically addressing UDIN duplication and document formatting. Despite these administrative issues, the company reported a strong consolidated net profit of ₹20.13 crore for the quarter ended September 2025, up from ₹3.51 crore in the previous year. However, the auditor highlighted that the German subsidiary, Venus Pharma GmbH, has a negative net worth of ₹1.32 crore, creating material uncertainty. Management expects the subsidiary's position to stabilize by the end of FY 2025-26.
- Consolidated Net Profit surged to ₹20.13 crore in Q2 FY26 compared to ₹3.51 crore in Q2 FY25
- Total Income for the quarter stood at ₹184.48 crore, up from ₹178.03 crore year-on-year
- Company clarified that UDIN duplication in audit reports was a clerical error and re-submitted documents
- German subsidiary Venus Pharma GmbH reported a negative net worth of ₹1.32 crore
- Basic EPS for the quarter improved significantly to ₹15.08 from ₹2.63 in the corresponding previous quarter
Venus Remedies Limited has been awarded an incentive of ₹11,77,50,000 under the Government of India's Production Linked Incentive (PLI) scheme. This marks the second disbursement for the company, which had previously received ₹10 crore under the same scheme. The total incentive received under this program now stands at approximately ₹21.78 crore. This cash inflow is expected to support the company's operational excellence and innovation in pharmaceutical manufacturing.
- Awarded ₹11,77,50,000 as the second disbursement under the PLI scheme
- Previously received a sum of ₹10 crore under the same government initiative
- Total incentives received under the PLI scheme now aggregate to ₹21.78 crore
- The incentive reinforces the company's commitment to pharmaceutical manufacturing and innovation
Venus Remedies Limited has received its first marketing authorization in Indonesia for the antibiotic combination Ceftazidime + Avibactam. This product is designed to treat serious infections caused by multi-drug resistant gram-negative pathogens, such as complicated urinary tract infections. Indonesia is a major pharmaceutical market in Southeast Asia, and this approval allows the company to leverage existing distribution partnerships for commercialization. This move strengthens the company's portfolio of high-barrier-to-entry therapies in the strategically important South-East Asian region.
- First marketing authorization for Ceftazidime + Avibactam in the Indonesian market
- Product targets serious multi-drug resistant gram-negative pathogens and urinary tract infections
- Indonesia represents one of the largest pharmaceutical markets in Southeast Asia
- Commercialization will be executed through existing distribution partnerships in the region
Venus Remedies Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by Registrar & Transfer Agent MUFG Intime India Pvt Ltd, confirms that all dematerialization requests for the quarter ended December 31, 2025, were processed within prescribed timelines. It further validates that physical share certificates were mutilated and cancelled after verification, with the depositories' names updated in the register of members. This is a standard administrative filing ensuring the integrity of the company's shareholding records.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Issued by Registrar & Transfer Agent MUFG Intime India Private Limited.
- Confirms that securities received for dematerialization are listed on the relevant stock exchanges.
- Confirms physical certificates were mutilated and cancelled after due verification.
- Verification of depository participant records completed within mandated SEBI timelines.
Venus Remedies Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent insider trading before financial disclosures. The window will remain closed until 48 hours after the declaration of the financial results for the period ending December 31, 2025. This is a standard regulatory procedure followed by all listed companies in India ahead of quarterly earnings reports.
- Trading window closure effective from January 1, 2026
- Applies to all designated persons under SEBI Insider Trading Regulations
- Closure pertains to the financial results for the period ending December 31, 2025
- Window will reopen 48 hours after the official declaration of results
Venus Remedies Limited has announced a special window for re-lodgement of transfer requests for physical shares, complying with SEBI Circular No. SEBI/MO/MIRSD/RSD-PoDIT/CIR/2025/97 dated July 02, 2025. The company has shared the notice to shareholders via social media platforms including Instagram, Facebook, LinkedIn, and X. Links to these social media posts have been provided to the Exchange to inform shareholders about this opportunity.
- Special window for re-lodgement of physical shares transfer requests
- Compliant with SEBI Circular No. SEBI/MO/MIRSD/RSD-PoDIT/CIR/2025/97
- SEBI circular dated July 02, 2025
- Company Secretary M. No. F8374
Venus Remedies Limited has released its monthly report regarding the re-lodgement of physical share transfer requests for the period July 7, 2025, to November 30, 2025. The report, filed under SEBI's 'Ease of Doing Investment' circular, shows minimal activity with only two requests received in total. Both requests, one in July and one in October, were processed but ultimately rejected. This filing is a standard regulatory compliance matter and does not impact the company's operational or financial performance.
- Total of 2 requests for share transfer cum demat were received between July and November 2025
- Zero requests were approved during the reporting period, with both received requests being rejected
- Processing time for the July request was 1 day, while the October request took 24 days to process
- No requests were received or processed during the months of August, September, and November 2025
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 7.72% YoY to ₹647.89 Cr in FY25, while standalone revenue grew 11.17% to ₹639.46 Cr. Growth was driven by critical care, anti-infectives, and oncology divisions.
Geographic Revenue Split
Not disclosed in specific percentages, but the company reported strong export momentum and expanded marketing efforts in key global markets including Europe, ASEAN, and Africa.
Profitability Margins
Net Profit Margin improved from 5.20% in FY24 to 7.96% in FY25. Consolidated Profit After Tax (PAT) grew 59.05% YoY to ₹45.31 Cr, while standalone PAT grew 72.34% to ₹52.56 Cr.
EBITDA Margin
EBITDA increased 18.7% YoY from ₹71.18 Cr in FY24 to ₹84.49 Cr in FY25, representing an EBITDA margin of approximately 13.04%.
Capital Expenditure
Not disclosed in absolute INR Cr for future periods, but the company is prioritizing 'sustainability-first construction' for all future sites and investing in digital infrastructure.
Credit Rating & Borrowing
The company was rated 'CRISIL D (ISSUER NOT COOPERATING)' as of October 2020. Interest costs are maintained low, at less than 1% of total revenues.
Operational Drivers
Raw Materials
Specific names not disclosed; categorized as 'imported raw materials' and components for pharmaceutical formulations.
Key Suppliers
Not disclosed in available documents; company uses multiple supplier contracts to mitigate disruption risks.
Capacity Expansion
Current capacity not disclosed in units; expansion plans focus on the Global Venus Fulfilment Centre (Global VFC) and automation of critical processes.
Raw Material Costs
Cost of material consumed remained largely at the previous year's level despite a 7.72% increase in consolidated revenue, indicating improved procurement efficiency.
Manufacturing Efficiency
Internal rejection rates were eliminated (0 rejections) in FY25, down from 1 in FY24 and 2 in FY23, through strengthened in-process controls.
Strategic Growth
Expected Growth Rate
7.72%
Growth Strategy
Growth will be achieved through the commercialization of intellectual property assets, completion of AMR licensing milestones (final €1.1 Cr payment), and expansion of digital literature with QR codes in domestic markets.
Products & Services
Pharmaceutical formulations in critical care, anti-infectives, oncology, and research-based products like VRP-034.
Brand Portfolio
Venus Remedies, Venus Pharma GmbH, Venus Care.
New Products/Services
VRP-034 received USFDA QIDP designation; company is focusing on marketing authorisations for IP-led formulations.
Market Expansion
Targeting further growth in European markets and domestic expansion through digital branding and social media strategies.
Strategic Alliances
AMR Licensing agreement (milestone completed with €1.1 Cr payment); collaboration with government Skill Sector councils for digital assessments.
External Factors
Industry Trends
The industry is shifting toward digital literature, automated quality management, and stricter compliance with EU GMP Annexe I and Schedule M updates.
Competitive Landscape
Competitive edge maintained through R&D-led formulations versus pure generic drug production.
Competitive Moat
Durable moat through 130+ secured patents, 25+ GMP certifications (including EU-GMP), and USFDA QIDP designation for research products.
Macro Economic Sensitivity
Sensitive to global demand fluctuations and economic uncertainties affecting pharmaceutical exports.
Consumer Behavior
Increasing demand for transparent product data, addressed by the company through digital literature and QR codes.
Geopolitical Risks
Global supply chain disruptions for raw materials and stringent global standards for injectables.
Regulatory & Governance
Industry Regulations
Compliance with EU GMP Annexe I (ORABS and Automatic Lyoloading) and Schedule M updates for sterile disinfectants.
Environmental Compliance
Investing in 'sustainability-first construction', Scope 3 emissions frameworks, and carbon-neutral roadmaps.
Taxation Policy Impact
Resolved all pending Income Tax matters; contingent liability of ₹33.44 Cr reduced to nil with refunds received.
Legal Contingencies
Previously reported contingent liability of ₹33.44 Cr related to Income Tax is now nil following favorable appellate decisions.
Risk Analysis
Key Uncertainties
Regulatory setbacks or negative publicity could impact global brand trust; IP disputes could undermine R&D efforts.
Geographic Concentration Risk
Not disclosed, but company has a presence in 51 countries across Europe, North America, and ASEAN.
Third Party Dependencies
Reliance on imported raw materials is a key dependency; mitigated by multiple supplier contracts.
Technology Obsolescence Risk
Mitigated by digital transformation initiatives including 21 CFR-compliant software and automated payment systems.
Credit & Counterparty Risk
Receivables quality improved through superior working capital management, resulting in ₹86.44 Cr operating cash flow.